Kaya Holdings, Inc. (OTCQB:KAYS) Criticizes FDA Rejection of MDMA Therapy for PTSD, Proposes Psilocybin as Alternative Treatment - Seite 2

These published studies, along with additional studies at Kings College, London and John Hopkins University in Baltimore have allowed a comparison of MDMA and psilocybin on matters of efficacy and duration, side effects, and safety profiles. A summary of the comparison reveals:

• The time of a psilocybin experience is typically longer than the MDMA experience, and this more prolonged session could provide more time for psychological processing and integration of insights gained during the experience.

While psilocybin typically produces a more introspective and insightful experience with visual and auditory hallucinations, MDMA typically enhances one's feelings of empathy and connection to others without hallucinations. The introspective nature of the psilocybin experience may facilitate deeper psychological integration compared to the shorter-lasting effects of MDMA.

The side effects of psilocybin generally milder than those of MDMA, which include changes in heart rate, dehydration, jaw clenching, nausea, anxiety and agitation, sweating and chills.

Psilocybin has a preferred safety profile with regard to potential for abuse and risk of developing a dependency, compared to MDMA.

For more information regarding The Sacred Mushroom and psilocybin,

or to make an appointment for Psilocybin Services, please go to Home Page - Psilocybin Services | The Sacred Mushroom (thesacredmushroompdx.com)

or send an email to [e-mail]

Disclaimer
The information set forth above is for general consumer understanding and education and should not be considered or used as a substitute for medical advice, diagnosis or treatment. Psilocybin is not an alternative to any prescription drug. A physician should be consulted prior to making any changes in prescription drug treatment.

The information set forth above and the information contained herein has not been evaluated by the FDA. Psilocybin is not intended to diagnose, treat or cure any disease. Results of psilocybin treatment may vary.

Psilocybin is not federally legal in the United States.

KAYS Shareholders and Other Interested Parties - Please Update Your Contact Information:
We routinely receive calls and emails from shareholders and other interested parties seeking an update on our operations. We are asking all KAYS shareholders and interested parties to email us and confirm their contact info. Please email [e-mail] with "KAYS shareholder update" in the subject line and include your name, address, phone number and number of shares you own so that we can make sure you receive all updates and respond to inquiries. If you would like to speak to someone at the Company, please call or text 954-480-3960 and someone will get right back to you.